# DSIP Dosage in the Research: Doses, Routes, and Half-Life

> DSIP dosage as studied in the research, not as advice. The doses, routes, and very short half-life reported in animal and 1980s human studies of the DSIP peptide.

The doses and routes scientists actually used — described for context, not as a protocol to follow.

## Read this first

Let's be clear up front, because this matters. This page describes DSIP dosage the way it appears in published studies — which animal got how much, by which route. It is not a how-to, and there is no human dose to recommend, because DSIP is not an approved drug and no validated human dosing exists [3]. We're walking through the research numbers so you understand the literature, not so anyone uses them. You'll notice the doses are scattered across very different units and routes, which is itself a sign of how unsettled this field is. Where a study used a specific amount in a specific species, we say so and cite it. Where the science is genuinely unknown — like the human half-life — we say that too.

## DSIP peptide dosage in human studies

When people search for DSIP peptide dosage, this is the human research they usually mean. The most frequently used human research dose was 25 nmol/kg of body weight, given intravenously. That is the dose in the 1981 chronic-insomnia study, where it improved sleep with the effect appearing in the second hour [2]; the same 25 nmol/kg IV dose was used in the ACTH study in men [4] and in the withdrawal pilot where 48 of 49 patients responded [7]. The chronic-pain pilot used IV DSIP on five consecutive days, then injections every 48 to 72 hours [9]. These are historical research protocols from small 1980s studies, reported here for context only — not dosing guidance, and not validated by any modern trial.

## DSIP dosage in animal studies

Animal doses ranged widely by species and goal. In rat growth-hormone work, doses of roughly 0.1 to 10 micrograms were given into the brain ventricles, with a minimal effective dose near 0.1 microgram. Rat neuroprotection studies used about 120 micrograms/kg intranasally, and rat anticonvulsant work used 0.1 to 1 mg/kg, most effective at the top of that range. The mouse longevity research used the Deltaran preparation at about 100 micrograms/kg (2.5 micrograms per mouse) subcutaneously, on five consecutive days each month [5]. Cat sleep studies used 120 nmol/kg subcutaneously. The sheer spread of these numbers — and the reported non-monotonic, "parabolic" dose-response, where intermediate doses can beat higher ones — is a major reason the literature is hard to interpret.

## Half-life and how long DSIP stays in the body

DSIP has a very short circulating half-life. A metabolic-clearance study in dogs, monkeys, and rats reported plasma half-lives on the order of only a few minutes, attributed to rapid breakdown by enzymes called aminopeptidases and binding to plasma proteins. No validated human pharmacokinetic profile exists, so how long DSIP persists in a person is not actually established. This rapid clearance is one reason researchers have explored more stable look-alikes, including the naturally phosphorylated form DSIP-P and the engineered fusion peptide in the 2024 mouse study, which was built specifically to survive longer and reach the brain [6].

## Routes and forms studied

Across the literature DSIP has been delivered intravenously (the main human route), into the brain ventricles (rodents), subcutaneously (cats and mice), and intranasally (rat neuroprotection), plus in cell-culture perifusion for lab work. The intranasal route is worth flagging because online interest in a DSIP peptide nasal spray is common, yet the only intranasal data is the rat neuroprotection work — there is no human nasal-spray study, no approved nasal product, and no established nasal dose. As a short peptide it is broken down quickly in plasma, and there is no pharmaceutical-grade product or stability standard — lyophilized research material is simply reconstituted in sterile or bacteriostatic water for laboratory use. None of this constitutes a usable human protocol; it is the experimental record, and it stops well short of anything a person could safely act on.

---

A patient, plain-English walk through the delta sleep-inducing peptide research — nine amino acids explained, the weak spots flagged, no clinic and no product behind it.